番茄社区app

Bradbury AW, Hall JA, Popplewell MA, et al. . BMJ. 2025;388:e080881.

Randomized trials have supported the use of surgical revascularization for patients with chronic limb-threatening ischemia when femoral-popliteal bypass is needed and adequate vein for the bypass conduit is available.

When endovascular revascularization is required because of inadequate vein availability, high patient risk, or patient preference, data to support the choice of endovascular device鈥攑lain balloon with or without bare metal stenting (PBA卤BMS), drug coated balloon with or without bare metal stenting (DCBA卤BMS), or drug-eluting stenting (DES)鈥攁re lacking.

This randomized trial (n = 481) compared the three treatment options; the main outcome of interest was amputation-free survival.

Over a 5-year follow up interval, death or amputation occurred in 66% of the PBA卤BMS group, 60% of the DCBA卤BMS group, and 58% of the DES group. The authors concluded that neither DCBA卤BMS nor DES conferred significant patient benefit compared with PBA卤BMS.